U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H18NO2.Cl
Molecular Weight 195.687
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHACHOLINE CHLORIDE

SMILES

[Cl-].CC(C[N+](C)(C)C)OC(C)=O

InChI

InChIKey=JHPHVAVFUYTVCL-UHFFFAOYSA-M
InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H18NO2
Molecular Weight 160.234
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546

Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
PROVOCHOLINE

Approved Use

Provocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma.

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.83 μg/mL
650 mg single, oral
dose: 650 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
80.19 μg × h/mL
650 mg single, oral
dose: 650 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.08 h
650 mg single, oral
dose: 650 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRANEXAMIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg/mL 5 times / day multiple, respiratory
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources:
unhealthy
Disc. AE: Bronchoconstriction...
AEs leading to
discontinuation/dose reduction:
Bronchoconstriction (severe)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bronchoconstriction severe
Disc. AE
16 mg/mL 5 times / day multiple, respiratory
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung.
2001-06
SCF-induced airway hyperreactivity is dependent on leukotriene production.
2001-06
Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle.
2001-06
Regulation of secretion from mucous and serous cells in the excised ferret trachea.
2001-06
Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs.
2001-06
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus.
2001-05
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model.
2001-05
Occupational asthma caused by exposure to cyanoacrylate.
2001-05
Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults.
2001-05
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.
2001-05
Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex.
2001-05
Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma.
2001-05
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal.
2001-05
Allergen-induced changes in airway responsiveness are not related to indices of airway edema.
2001-05
Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics.
2001-05
Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects.
2001-05
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans.
2001-05
Airways hyperresponsiveness and the effects of lung inflation.
2001-04-18
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2).
2001-04-15
Bronchial hyperactivity in bakers and its relation to atopy and skin reactivity.
2001-04-10
Effect of natural allergen exposure on non-specific bronchial reactivity in asthmatic farmers.
2001-04-10
Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen.
2001-04
Reduction in atrial defibrillation threshold by a single linear ablation lesion.
2001-04
Changes in indices of airway hyperresponsiveness during one year of treatment with inhaled corticosteroids in patients with asthma.
2001-04
Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma.
2001-04
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways.
2001-04
Conditioned medium from hypoxic cytotrophoblasts alters arterial function.
2001-04
Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up.
2001-04
Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma.
2001-04
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families.
2001-04
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity.
2001-04
Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma.
2001-04
Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats.
2001-04
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.
2001-03-27
Effects of BCG on ovalbumin-induced bronchial hyperreactivity in a guinea pig asthma model.
2001-03
Comparison of the effects on drug concentrations, electrophysiologic parameters, and termination of atrial fibrillation in dogs when procainamide and ibutilide are delivered into the right atrium versus intravenously.
2001-03
Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum.
2001-03
Airway responses to a diluent used in the methacholine challenge test.
2001-03
High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma.
2001-03
Incidence and host determinants of probable occupational asthma in apprentices exposed to laboratory animals.
2001-03
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge.
2001-03
The effect of immunotherapy on nonspecific bronchial hyperresponsiveness in bronchial asthma and allergic rhinitis.
2001-02
Respiratory effects of a single dive to 50 meters in sport divers with asymptomatic respiratory atopy.
2001-02
Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis.
2001-01
Methacholine inhalation challenge: a shorter, cheaper and safe approach.
2001-01
Noninvasive method to measure airway obstruction in nonanesthetized allergen-sensitized and challenged mice.
2001
Bronchoconstrictor reactivity to NKA in allergic dogs: a comparison to histamine and methacholine.
2001
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man.
2001
Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics.
2001
Relationship of airway responsiveness with airway morphometry in normal and immunized rabbits.
2001
Patents

Sample Use Guides

Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration: Respiratory
In Vitro Use Guide
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:13 GMT 2025
Record UNII
0W5ETF9M2K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHACHOLINE CHLORIDE
INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
PROVOCHOLINE
Preferred Name English
NSC-757090
Code English
METHACHOLINE CHLORIDE [MART.]
Common Name English
METHACHOLINE CHLORIDE [USP-RS]
Common Name English
Methacholine chloride [WHO-DD]
Common Name English
(±)-(2-HYDROXYPROPYL)TRIMETHYLAMMONIUM CHLORIDE ACETATE
Systematic Name English
METHACHOLINE CHLORIDE [JAN]
Common Name English
METHACHOLINE CHLORIDE [USP MONOGRAPH]
Common Name English
METHACHOLINE CHLORIDE [VANDF]
Common Name English
1-PROPANAMINIUM, 2-(ACETYLOXY)-N,N,N-TRIMETHYL-, CHLORIDE, (±)-
Systematic Name English
Acetyl-?-methylcholine chloride
Common Name English
METHACHOLINE CHLORIDE [MI]
Common Name English
methacholine chloride [INN]
Common Name English
METHACHOLINE CHLORIDE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1937
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
Code System Code Type Description
RXCUI
40165
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY RxNorm
EVMPD
SUB08832MIG
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
DAILYMED
0W5ETF9M2K
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
NCI_THESAURUS
C47607
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
RS_ITEM_NUM
1396364
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID7023271
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
INN
3161
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-537-2
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL978
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
MESH
D016210
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
CAS
62-51-1
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
PUBCHEM
6114
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
MERCK INDEX
m7282
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY Merck Index
DRUG BANK
DBSALT001175
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
FDA UNII
0W5ETF9M2K
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
NSC
757090
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
SMS_ID
100000081225
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
CHEBI
50142
Created by admin on Mon Mar 31 18:32:13 GMT 2025 , Edited by admin on Mon Mar 31 18:32:13 GMT 2025
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
USP
Related Record Type Details
ACTIVE MOIETY